Nicolas Jouand

TL;DR: It is demonstrated that CD8+ T cells internalize exosomes from different tumor types even if these cells do not internalize vesicles as readily as other immune cells, and suggested that miRNAs in melanoma-derived exosome aid tumor immune evasion and could be a therapeutic target.

TL;DR: It is suggested that HLA-E/β2m–CD94/NKG2A represents a new druggable inhibitory immune checkpoint, preferentially expressed in microsatellite instable tumors, but also in a subgroup of micros Satellite stable tumors, leading to a new opportunity in colorectal cancer immunotherapies.

TL;DR: It is documented that the frequency of circulating PD-1+TIGIT+ (DPOS) CD8+ T-cells after 1 month of anti-PD-1 therapy was associated with clinical response and overall survival.

TL;DR: HCMV induces strong and life-long lasting HLA-EUL40 CD8 T cells with potential allogeneic or/and autologous reactivity that take place selectively in at least a third of infections according to virus strain and host HLA concordance.

TL;DR: From a clinical point of view, these results open a promising alternative for immunotherapies based on NKG2A blockade in CRC, which could be performed alone or in combination with other IC inhibitors, adoptive cell transfer or therapeutic vaccination.